Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 10;16(8):18601-27.
doi: 10.3390/ijms160818601.

Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children

Raffaella Franca  1 , Gabriele Stocco  2 , Diego Favretto  3 , Nagua Giurici  4 , Giuliana Decorti  5 , Marco Rabusin  6
Affiliations
Review

Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children

Raffaella Franca et al. Int J Mol Sci. .

Abstract

Hematopoietic stem cell transplantation (HSCT) is an established therapeutic procedure for several congenital and acquired disorders, both malignant and nonmalignant. Despite the great improvements in HSCT clinical practices over the last few decades, complications, such as graft vs. host disease (GVHD) and sinusoidal obstructive syndrome (SOS), are still largely unpredictable and remain the major causes of morbidity and mortality. Both donor and patient genetic background might influence the success of bone marrow transplantation and could at least partially explain the inter-individual variability in HSCT outcome. This review summarizes some of the recent studies on candidate gene polymorphisms in HSCT, with particular reference to pediatric cohorts. The interest is especially focused on pharmacogenetic variants affecting myeloablative and immunosuppressive drugs, although genetic traits involved in SOS susceptibility and transplant-related mortality are also reviewed.

Keywords: graft vs. host disease; hematopoietic stem cell transplantation; pharmacogenetics; sinusoidal obstructive syndrome.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Passweg J.R., Baldomero H., Peters C., Gaspar H.B., Cesaro S., Dreger P., Duarte R.F., Falkenburg J.H.F., Farge-Bancel D., Gennery A., et al. Hematopoietic SCT in Europe: Data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant. 2014;49:744–750. doi: 10.1038/bmt.2014.55. - DOI - PMC - PubMed
    1. Arnaout K., Patel N., Jain M., El-Amm J., Amro F., Tabbara I.A. Complications of allogeneic hematopoietic stem cell transplantation. Cancer Investig. 2014;32:349–362. doi: 10.3109/07357907.2014.919301. - DOI - PubMed
    1. Servais S., Beguin Y., Baron F. Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin. Emerg. Drugs. 2013;18:173–192. doi: 10.1517/14728214.2013.798642. - DOI - PubMed
    1. Huezo-Diaz P., Uppugunduri C.R., Tyagi A.K., Krajinovic M., Ansari M. Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children. Curr. Drug Metab. 2014;15:251–264. doi: 10.2174/1389200215666140202214012. - DOI - PubMed
    1. Relling M.V., Gardner E.E., Sandborn W.J., Schmiegelow K., Pui C.H., Yee S.W., Stein C.M., Carrillo M., Evans W.E., Klein T.E. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 2013;89:387–391. doi: 10.1038/clpt.2010.320. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources